- Open Access
Efficacy and safety of a novel topical agent for gallstone dissolution: 2-methoxy-6-methylpyridine
Journal of Translational Medicine volume 17, Article number: 195 (2019)
Although methyl-tertiary butyl ether (MTBE) is the only clinical topical agent for gallstone dissolution, its use is limited by its side effects mostly arising from a relatively low boiling point (55 °C). In this study, we developed the gallstone-dissolving compound containing an aromatic moiety, named 2-methoxy-6-methylpyridine (MMP) with higher boiling point (156 °C), and compared its effectiveness and toxicities with MTBE.
The dissolubility of MTBE and MMP in vitro was determined by placing human gallstones in glass containers with either solvent and, then, measuring their dry weights. Their dissolubility in vivo was determined by comparing the weights of solvent-treated gallstones and control (dimethyl sulfoxide)-treated gallstones, after directly injecting each solvent into the gallbladder in hamster models with cholesterol and pigmented gallstones.
In the in vitro dissolution test, MMP demonstrated statistically higher dissolubility than did MTBE for cholesterol and pigmented gallstones (88.2% vs. 65.7%, 50.8% vs. 29.0%, respectively; P < 0.05). In the in vivo experiments, MMP exhibited 59.0% and 54.3% dissolubility for cholesterol and pigmented gallstones, respectively, which were significantly higher than those of MTBE (50.0% and 32.0%, respectively; P < 0.05). The immunohistochemical stains of gallbladder specimens obtained from the MMP-treated hamsters demonstrated that MMP did not significantly increase the expression of cleaved caspase 9 or significantly decrease the expression of proliferation cell nuclear antigen.
This study demonstrated that MMP has better potential than does MTBE in dissolving gallstones, especially pigmented gallstones, while resulting in lesser toxicities.
Cholelithiasis is a highly prevalent disease, particularly in developed countries, with incidence rates of 10–15% in the adult population, indicating that 20–25 million Americans have gallstones . Laparoscopic cholecystectomy is considered the cornerstone treatment for symptomatic cholelithiasis. However, clinicians are occasionally confronted with inoperable patients because of the operative risks or refusal of patients. To better cope with such situations, several topical gallstone-dissolving agents have been developed, which are administrated via the percutaneous transhepatic route.
Of all the gallstone-dissolving compounds, methyl tert-butyl ether (MTBE) is a representative solvent and the only such drug currently used. MTBE is an alkyl ether similar to diethyl ether, an anesthetic agent. Unlike the lower boiling point of diethyl ether (35 °C), MTBE has a relatively higher boiling point (55 °C); thus, it is liquid at body temperature [2, 3]. Acceptable dissolubility of MTBE was validated by a variety of studies, including a large survey of 803 patients across 21 European hospitals that demonstrated a dissolution rate of 96.6% (724/804) with a low rate of toxic side effects and complications . However, the widespread use of MTBE is limited by its side effects, such as nausea, upper abdominal pain, duodenitis, mild-to-moderate anesthesia, and hemolysis [5,6,7,8,9,10,11,12,13,14]. A substantial proportion of these side effects could be attributed to its relatively low boiling point and the resultant higher evaporation; the evaporation rate of MTBE is 8.0 (i.e., 8.0 times higher than that of standard n-butyl acetate), and thus is classified as “fast evaporating”.
In this study, we first developed a gallstone-dissolving compound with an aromatic moiety, named 2-methoxy-6-methylpyridine (MMP). To date, various compounds have been used to dissolve gallstones, including MTBE, heparin, bile acid, d-limonene, mono-octanoin, ethylenediamine tetraacetic acid (EDTA), and sodium hexametaphosphate, all of which are composed of aliphatic chains [15, 16]. MTBE has an asymmetric chemical structure that contains an ether functional group. With an oxygen atom in between, one side of MTBE is the bulky tert-butyl group and the other side is a simple methyl group. In MMP, the bulky aliphatic tert-butyl group of MTBE is replaced with pyridine, an aromatic group. The compounds with an aromatic ring tend to have a relatively higher boiling point and lower vapor pressure . MMP, thus, has a relatively higher boiling point (156 °C) and evaporates less, raising the possibility of having lesser toxicities while maintaining similar dissolubility as MTBE. In this study, we intended to determine whether MMP could be an alternative to MTBE by comparing their gallstone dissolubility and toxicities.
Chemicals and reagents
MTBE was obtained from Sigma-Aldrich (St. Louis, MO). MMP was produced in the Korea Research Institute of Chemical Technology (KRICT, Daejeon, Republic of Korea).
Nuclear magnetic resonance spectroscopy
Nuclear magnetic resonance (NMR) was used to measure the chelation effect of the gallstone-dissolving compounds, MTBE and MMP. 1-h NMR spectra were recorded on Bruker INOVA 400 MHz NMR spectrometers (BRUKER, Fȁllanden, Switzerland) at 25 °C. Chemical shifts are reported in parts per million (ppm). Data for 1-h-NMR are reported as follows: chemical shift (δ ppm) (integration, multiplicity, and coupling constant [Hz]). Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, sep = septet, dd = doublet of doublets, and m = multiplet. The residual solvent peak was used as an internal reference.
The thermogravimetric analysis (TGA), differential thermal analysis (DTA), and derivative of TGA (DTG) curves were recorded for each solvent using Thermo plus EVO II TG 8120 series thermal analyzer (RIGAKU, Tokyo, Japan). All three thermo-curves, TG, DTG, and DTA, were recorded simultaneously within temperatures of 25–100 °C in an air atmosphere. The thermo-curves were recorded for heating rates of 5 °C/min. In all the thermo-curves, the sample mass initially weighed between 4 and 5 mg. The kinetic parameters were calculated using the data obtained from the recorded thermo-curves by employing non-mechanistic Kissinger evaluation method.
Determination of gallstone components
We used the following assay kits to determine the components of gallstones; Cholesterol Enzymatic Assay Kit (Xpressbio, Fredrick, MD) for cholesterol, Triglyceride Quantification Kit (Cell Biolabs, San Diego, CA) for triglycerides, Bilirubin Assay Kit (Cell Biolabs) for bilirubin, and Phosphate Colorimetric Assay Kit (Biovision, Mountain View, CA) for bilirubin. The gallstones were homogenized with the substances described in each assay kit and the supernatant was collected for assay. After incubation for a determined period at 37 °C in the assay buffer, the absorbance was measured using a microplate reader (model 680; Bio-Rad, Hercules, CA).
Measurement of in vitro gallstone dissolubility
We collected gallstones following cholecystectomy in patients with gallstones. The study was approved by the Ethics Committee of Daejeon St Mary’s hospital, the Catholic University of Korea (IRB code: DC09FZZZ0045). We first determined the cholesterol contents in the collected gallstones using Cholesterol Enzymatic Assay Kit (Xpressbio, Fredrick, MD). Based on the cholesterol content, the gallstones were categorized into cholesterol (cholesterol content > 70%), mixed (70–30%), and pigmented gallstones (< 30%). The gallstones were air-dried, weighed, and preserved in saline. Subsequently, they were matched for size, weight, and shape for preparation for the dissolubility measurements. The three types of gallstones, with a mean weight of 43 ± 4 mg, were placed in separate glass containers, to which 10 ml aliquots of MTBE or MMP were added; the aliquots were aspirated and replaced every hour. The glass containers were gently stirred at 50 rpm on the reactor (VS-8480SF; Vision Co., Daejeon, Republic of Korea) at 37 °C for 24 h. Gallstone dissolubility according to each solvent was determined by measuring the dry weights of the gallstones at three different intervals (4, 8, and 24 h). Specifically, in vitro gallstone dissolubility (%) of each solvent was defined as (the average weight of untreated gallstones − the average weight of gallstones after solvent treatment)/the average weights of untreated gallstones.
Cell viability assay
Cell viability of human gallbladder epithelial cells (hGBECs) was evaluated with 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (water soluble tetrazolium salt; ST-1) assay using EZ-Cytox Cell Proliferation Assay kit (Itsbio, Seoul, Republic of Korea) according to the manufacturer’s instructions. Additionally, we performed another series of cell viability assay for the following cells using Cyto X cell viability assay kit (LPS solution Co., Daejeon, Republic of Korea); Vero (African green monkey kidney, ATCC#81-CCL), L929 (mouse fibroblast, ATCC #2148-CRL), NIH 3T3 (mouse embryonic fibroblast, ATCC #1658-CRL), and CHO-K1 (Chinese hamster ovary, ATCC #61-CCL) cells.
In vivo animal experiments
In vivo dissolubility study using a hamster model of gallstones
All animal studies were carried out in compliance with the guidelines of the Institute for Laboratory Animal Research in Korea. This animal study was approved by the Institutional Animal Care and Use Committee of the Clinical Research Institute at Daejeon St. Mary’s Hospital at the Catholic University of Korea (IRB No. CMCDJ-AP-2016-004). For in vivo validation of each solvent, we used 10-week-old female Syrian golden hamsters (Mesocricetus auratus, Harlan Sprague–Dawley Indianapolis, IN). Hamsters in each group were fed a different diet as follows for 4 months: the hamsters in the control group (N = 10) were fed a normal diet, while those in group CG (the group with cholesterol gallstones, N = 50) were fed a general rodent diet with 0.5% cholesterol, and those in group PG (the group with pigmented gallstones, N = 50) were fed a diet rich in carbohydrates. The diet compositions of each group are shown in Additional file 1: Table S1. The body weights of the hamsters were measured weekly. After 4 months of diet, the hamsters with gallstones were identified using abdominal ultrasonography and selected for further experiments. We directly infused the control material (DMSO) and each solvent into the gallbladder of the hamsters with cholesterol (n = 40) and pigmented gallstones (n = 40), respectively, after laparotomy under general anesthesia. After laparotomy under general anesthesia, each solvent was infused into the gallbladder using a 30-gauge syringe; after complete aspiration of the bile, the gallbladder was cautiously filled with a similar volume (0.1 ml) of dimethyl sulfoxide (DMSO), MTBE, and MMP, respectively. After 24 h, the hamsters were euthanized, and the gallstones and several pieces of tissues (liver, kidney, and gallbladder) were collected for further evaluations. Gallstone dissolubility of each solvent was determined by comparing the weights of solvent-treated gallstones and control (DMSO)-treated gallstones. Specifically, in vivo gallstone dissolubility (%) of each solvent was defined as (the average weight of DMSO-treated gallstones − the average weight of gallstones after solvent treatment)/the average weights of DMSO-treated gallstones.
In vivo acute toxicity test in mice
Seven-week-old female Institute of Cancer Research (ICR) mice were purchased from Orient Bio, Inc. (Seongnam, Republic of Korea). The mice were allowed to acclimatize to their new environment for 7 days and were maintained in an environment with temperature 23 ± 3 °C, humidity 50 ± 10%, 12-h light–dark cycle with 150–300 lx, and ventilation at 10–20 times/h. For the acute toxicity study, the mice were divided into 3 groups (n = 7, respectively). After starvation for 24 h, the control group was given 5% DMSO, while the treatment groups received MTBE and MMP, respectively, at 2000 mg/kg prepared in a corn oil through oral gavage. The general behavior (skin, respiration, tremors, lethargy, or sleep), body weight, and mortality were monitored for 14 days.
Measurement of Zebrafish locomotor activity according to each solvent
Zebrafish were maintained under standard conditions as previously reported [18,19,20]. To monitor the locomotor activity, larval zebrafish at 5 days post-fertilization were placed in individual wells of a 96-well plate with 100 μl embryonic medium. Then, 100 μl of MTBE and MMP were added to a final concentration of 1 mM, respectively. After the treatment, changes were monitored at 28 °C for 60 min using DanioVision and EthoVision 10 XT locomotion tracking software (Noldus, Netherlands).
All data were analyzed with SPSS 11.0 software (SPSS Inc., Chicago, IL), and are presented as mean ± standard deviation (SD). Statistical comparisons between the groups were determined using the Kruskal–Wallis test. P < 0.05 was considered statistically significant. All authors had access to the study and reviewed and approved the final manuscript.
Additional materials and methods
Additional and more detailed information regarding the experimental procedures are fully described in Additional file 2: Materials and methods.
Determination of basic characteristics of MMP
Table 1 summarizes the structural and functional comparisons between MTBE and MMP. MMP has a structure wherein the tert-butyl group in MTBE is replaced by a bulky aromatic functional group, thus, resulting in elevation of the boiling point from 55 (MTBE) to 156 °C (MMP). A substantial proportion of MTBE toxicities are related to higher evaporation caused by a relatively low boiling point; therefore, MMP is expected to have relatively lesser toxicity due to its higher boiling point. Additionally, contrasted by MTBE, which has only one heteroatom oxygen, MMP has two heteroatoms (nitrogen and oxygen) in the form of a tweezer, which increases the possibility of stably trapping the cations in gallstones by chelate effect, which refers to an enhanced affinity toward a metal atom by a compound that is attached to the metal atom in a cyclic or ring structure. Chelate effect accelerates the dissolution of gallstones, as demonstrated by EDTA, which potentiates calcium stone dissolution by chelating the calcium component of gallstones . We herein attempted to determine the strength of chelate effect of each solvent (MTBE and MMP) using proton NMR, because the chemical shift of the intrinsic proton is expected to change according to the chelate effect between lone-pair electrons of the heteroatom and cation (Fig. 1a, b). To validate this concept, we used Co(ClO4)2·6H2O as the Co2+ provider because Co(ClO4)2·6H2O is likely to have independent cations due to the bulky anion ClO42−. When 0.5 equivalent of Co(ClO4)2·6H2O was added to solvents (MTBE and MMP), the chemical shifts were negligible (0.19 and 0.18 ppm, respectively). However, when the equivalent of Co(ClO4)2·6H2O was increased to 1.0–2.0 relative to the solvents, MMP exhibited considerably higher chemical shift than did MTBE (0.33–0.65 ppm vs. 0.50–1.03 ppm) (Fig. 1a, b), suggesting an enhanced affinity by chelate effect between MMP and Co2+. Other data supporting enhanced chelate effect by MMP were presented in Additional file 3: Fig. S1, Additional file 4: Fig. S2, Additional file 5: Fig. S3, Additional file 6: Fig. S4, Additional file 7: Fig. S5, and Additional file 8: Fig. S6.
Next, TGA was used to determine the stability of each solvent with increasing temperatures (Fig. 1c, d). In MTBE, we could not attain TGA data, because MTBE was already volatile at 25 °C and left no analytical residue. However, MMP progressively evaporated as the temperature increased from 20 to 70 °C and demonstrated the most abrupt change at 57 °C.
Classification of gallstones according to their components
Based on the literature, we classified gallstones based on their cholesterol content (≥ 70%, 70–30%, and < 30%) into cholesterol, mixed, and pigmented gallstones, respectively . Figure 2a shows the representative gross and cross sectional appearances of each type of gallstones. Cholesterol enzymatic assay revealed that the cholesterol contents were 84.3 ± 5.7% for cholesterol stones, 62.0 ± 3.9% for mixed stones, and 17.7 ± 0.2% for pigmented stones (Fig. 2b, c). In addition to cholesterol content, gallstones of each type demonstrated quite different compositions from other types of gallstones; for instance, pigmented stones contained significantly higher concentrations of phosphate and calcium than cholesterol stones.
Effects of each solvent on human gallbladder epithelial cells
We investigated the direct toxicities of each solvent on hGBECs. Cell viability tests revealed that the viability of hGBECs did not significantly decrease with elevating concentrations of MTBE and MMP up to 1.0 M, suggesting the negligible effects of both solvents on the viability of GBECs (Fig. 3a). Next, we performed Western blot analysis to determine the expression of the markers that reflect cell proliferation (PCNA), anti-apoptosis (Mcl-1), and apoptosis (BAX) with increasing concentration of each solvent (Fig. 3b). With increasing MTBE concentrations, there were sharp rises in the expression of PCNA and BAX, and fall in the expression of Mcl-1. MMP induced similar changes in these markers as MTBE; however, the changes were not as prominent as MTBE, and there was even a drop in the expression of BAX at a higher concentration (1 mM).
In vitro determination of gallstone dissolubility by each solvent
To determine the dissolubility of each solvent according to the type of gallstone, we compared the dry weights of human gallstones at three different time-points (4, 8, and 24 h) after they directly reacted with each solvent. Gallstone dissolubility was calculated as the difference in the weights of gallstones between pretreatment and the determined time intervals. In cholesterol gallstones, MMP dissolubility was significantly better than MTBE dissolubility at 8 h and 24 h (P < 0.05) (Fig. 3c). In mixed gallstones, the two solvents demonstrated similar dissolubility, except for temporal higher dissolubility of MMP at 4 h (Fig. 3d). In pigmented gallstones, MMP dissolubility was significantly better than MTBE dissolubility at 4 h, 8 h and 24 h (P < 0.05) (Fig. 3e). After 8 h, whereas MTBE demonstrated 58.5%, 44.5%, and 22.2% dissolubility, MMP demonstrated 73.5%, 47.5%, and 37.2% dissolubility for cholesterol, mixed, and pigmented gallstones, respectively. Furthermore, after 24 h, whereas MTBE showed 65.7%, 54.2%, and 29.0% dissolubility, MMP showed 88.2%, 61.0%, and 50.8% dissolubility for cholesterol, mixed, and pigmented gallstones, respectively.
Determination of systemic effects and in vivo gallstone dissolubility by each solvent
We established the hamster models having cholesterol gallstones (CG group) and pigmented gallstones (PG group) with the individual 3-month diet protocols as described earlier . During the course of feeding, the hamsters of each group showed consistent increases in body weights (Additional file 9: Fig. S7), and at the end of the feeding period, gallstones were found in 88% (44/50) of CG group, and 82% (41/50) of PG group. After detecting gallstones by abdominal ultrasonography, we randomly assigned the hamsters with cholesterol gallstones (N = 40) and pigmented gallstones (N = 40) into DMSO (control; n = 10), MTBE (n = 15), and MMP (n = 15) groups, respectively. Subsequently, we directly infused each material into the gallbladder of the hamsters with each type of gallstones, respectively, after laparotomy under general anesthesia.
First, to determine whether solvent infusion evokes a systemic inflammatory response, we measured the serum concentrations of proinflammatory mediators (IL-6 and TNF-α) by ELISA at 24 h of intracystic infusion. While MTBE significantly increased the serum levels of IL-6, MMP did not in both hamster models of cholesterol and pigmented gallstones (Fig. 4a). Additionally, whereas MTBE increased the serum levels of TNF-α, MMP decreased the levels of TNF-α in both models (Fig. 4b). Subsequently, we determined the dissolubility of each solvent by comparing the weights of the residual gallstones at 24 h after infusion (Fig. 4c). DMSO was used as the control material. In CG group, MTBE demonstrated 50.0% dissolubility, while MMP demonstrated 59.0% dissolubility, and the difference was statistically significant (P < 0.05) (Fig. 4d, left). Moreover, PG group was found to have far more significant differences; whereas MTBE showed 32.0% dissolubility, MMP showed 54.3% dissolubility (P < 0.05) (Fig. 4d, right). Therefore, we could conclude that MMP exhibited significantly higher dissolubility than MTBE in the hamster models with gallstones, especially pigmented gallstones.
Determination of in vivo toxicity of each solvent
To determine the toxic effects of each solvent on the liver and kidney, we performed histological evaluations using the tissues obtained from the hamsters at 24 h after intra-cystic infusion of each solvent. On microscopic observation with hematoxylin and eosin stains, the liver and kidney tissues of both solvent-treated hamsters were well preserved and did not show any visible signs of injury (Fig. 5a). Next, to determine the direct tissue toxicity of each solvent, we performed immunohistochemical (IHC) analysis of the gallbladder specimens obtained from the solvent-treated hamsters. The IHC panel included stains for representative markers of pro-apoptosis (cleaved caspase-3) and proliferation (PCNA). The expression of cleaved-caspase 3 was far more prominent after MTBE infusion than it was after MMP infusion in both CG and PG groups (P < 0.05) (Fig. 5b, left). Additionally, MTBE infusion far more significantly decreased the expression of PCNA than did MMP infusion (P < 0.05), suggesting a higher toxicity of MTBE over MMP, particularly in CG group (Fig. 5b, right).
Comprehensive testing of in vitro and in vivo toxicities of each solvent in various models
To further determine the in vitro toxicities of each solvent, we performed cell viability assay of various cell lines, including Vero cells, L929 cells, and CHO-K1 cells (Fig. 6a). We found that both solvents did not decrease cell viability of these cell lines, at least up to 1.0 M concentration of each solvent.
Next, for determining the central nervous system (CNS) toxicity of each solvent, we tracked larval zebrafish locomotion in 1 mM MTBE and MMP, respectively, over 60 min (Fig. 6b). The locomotor activity was normalized against DMSO as the control, and presented as a percentage. It was found that MTBE increased the locomotor activity during the first 6 min; however, MMP reduced it during the same period. Consequently, such differences were offset when the total sum of locomotor activities were counted over the observation period.
Finally, to determine the in vivo acute toxicity arising from a single exposure, the mortality, body weight changes, and general behaviors of the mice were monitored during 14 days after oral administration of each solvent at a dose of 2000 mg/kg (Fig. 6c). On the second day of the experiment, the same number of mice (3/7, 42.9%) were found to be dead in both groups administrated either MTBE or MMP, respectively. Those animals presented abnormal behaviors, including wheezing, tremors, and ataxia until death without noticeable differences between each group. Similar, but not pronounced, behaviors were also observed in the survived animals of the same group, and the behavior patterns were similar in both groups. In addition, the mice administrated with MMP were found slightly underweight during the first 7 days and, subsequently, recovered thereafter. Subsequently, after euthanizing the mice on 1 day and 14 days after oral administration, respectively, we obtained the specimens of liver, kidney, heart and lung, for the determination of histological effects of each solvent. Immunohistochemistry was performed for the markers of proliferation (PCNA), apoptosis (caspase 3 and Bax), and anti-apoptosis (survivin). On 1 day (Additional file 10: Fig. S8) as well as 14 day, the mice treated with MMP showed higher expression of PCNA, lesser expression of caspase 3 and Bas, and higher expression of survivin than the mice with MTBE (all Ps < 0.05) (Fig. 6d and Additional file 11: Fig. S9), suggesting the lesser tissue toxicity of MMP.
This is the first validation report of MMP, the gallstone-dissolving compound containing an aromatic moiety. To determine the dissolubility and toxicities of MMP, both in vitro and in vivo experiments were performed using human gallstones and an animal model of gallstones, respectively. Throughout the experiments, MMP demonstrated dissolubility similar to or better than that of MTBE towards both cholesterol and pigmented gallstones, while maintaining lesser toxicities. We believe that the chelate effect of MMP resulted in its improved dissolubility, while its higher boiling point (156 °C) resulted in fewer toxicities. We, thus, believe that MMP could be an attractive alternative to MTBE.
Until now, numerous investigators have developed, or applied, a variety of compounds in dissolving gallstones. The compounds include MTBE, heparin, bile acid, d-limonene, mono-octanoin, EDTA, and sodium hexametaphosphate, all of which are composed of aliphatic chains . Of these, MTBE is the only compound currently available. Although clinical studies have not reported critical toxicities of MTBE to date [4, 24, 25], several studies call into question the safety of MTBE. After administration, MTBE could be absorbed into the duodenum, leading to somnolence, nausea or vomiting [5,6,7,8,9, 11,12,13,14], it can also be systemically absorbed, resulting in hemolysis and reversible kidney injury . It was reported that inhalation of MTBE led to a statistically significant increase in kidney tumors and liver tumors in rats . Furthermore, MTBE has resulted in the development of cancers in many organs and tissues, which were similar to those caused by exposure to equal doses of carcinogens such as benzene, vinyl chloride, and 1,3-butadiene . Oral exposure to MTBE has been shown to cause dose-dependent, statistically significant increases in carcinomas such as lymphoma, leukemia, and Leydig cell carcinoma of the testes in rats . These dismal outcomes of MTBE motivated us to attempt to develop a novel gallstone-dissolving compound.
Basically, MMP is an MTBE analog with an aromatic moiety. MTBE is an asymmetric chemical compound with an ether functional group; one side of MTBE has a bulky tert-butyl group and the other side has a simple methyl group. MMP has a structure wherein the bulky aliphatic tert-butyl group of MTBE is replaced with an aromatic functional group while keeping the methyl group intact on the other side. The compounds with an aromatic ring have a relatively higher boiling point and lower vaporized pressure. MMP thus boils at a relatively higher temperature (156 °C) and, thus, evaporates less at room temperature, resulting in lesser toxicities while preserving the dissolubility of MTBE.
Our study suggests that the improved dissolubility of MMP is partly because it acts as a chelating ligand. Chelate is a complex compound consisting of a central metal atom and a large molecule (a ligand) that is attached to the metal atom in a cyclic manner. The chelate effect, thus, refers to the enhanced affinity of chelate ligands for a metal ion compared to the affinity of the non-chelating ligands. The chelate effect promotes gallstone dissolubility, as demonstrated by the enhanced dissolubility of calcium stones by EDTA, the representative chelating agent . MTBE does not have a chelating property because it has only one heteroatom with a lone pair of electrons. In contrast, MMP has two nearby heteroatoms with lone pair electrons, thus enabling to chelate the calcium component in gallstones. Additionally, the aromatic ring in MMP, named pyridine, has the advantage of being miscible with water and virtually all organic solvents, thereby facilitating gallstone dissolution. In the NMR test, we found that when the equivalent of Co(ClO4)2·6H2O was increased to 1.0–2.0 equivalents relative to the solvents, MMP exhibited considerably higher chemical shift than did MTBE, suggesting the enhanced affinity by chelate effect between MMP and Co2+. Our in vitro and in vivo studies demonstrated that MMP showed higher dissolubility than MTBE in both models of cholesterol and, more prominently, pigmented gallstones. Therefore, we believe that MMP potentiates the dissolubility of calcium-rich pigmented gallstones by chelating the calcium component, which needs to be validated in further studies.
MTBE or MMP are basically cholesterol solvents; therefore, they exhibit higher dissolubility for cholesterol gallstones than pigmented gallstones. In our in vitro study, whereas MTBE showed 65.7%, 54.2%, and 29.0% 24-h-dissolubility, MMP showed 88.2%, 61.0%, and 50.8% 24-h-dissolubility for cholesterol, mixed, and pigmented gallstones, respectively. The higher dissolubility for cholesterol gallstones is clinically preferable because most gallstones predominantly consist of cholesterol (> 85%) in the developed countries [30, 31].
Currently, topical gallstone-dissolving agents are restrictively available for patients who refuse surgery or are at high risk of surgery, possibly due to the concerns for their serious toxicities as well as the wide recognition of laparoscopic cholecystectomy as a safe operation. In addition, it remains controversial whether the complete removal of gallbladder can be justified in patients with gallstones with a functioning gallbladder, because although it is minimal, surgery inevitably accompanies a certain degree of operative risks and occasionally leads to postcholecystectomy syndrome . Finally, although still controversial, numerous epidemiological investigations and meta-analyses indicate that cholecystectomy can be a risk factor for gastrointestinal cancers [33,34,35,36,37]. The reason is frequently attributed to the deleterious effects of bile acid exposure; it acts like a carcinogen, in terms of enhancing DNA damage, stimulating mutation, inducing apoptosis in the short term, and ultimately promoting apoptosis resistance in the long term . Therefore, we believe that there are still indications for gallstone-dissolving solvents in lieu of laparoscopic cholecystectomy.
Several obstacles are placed in front of the popular use of gallstone dissolution therapy. The first concern is high incidence of stone recurrence. In a study of enrolling 803 patients with gallstones who had received contact litholysis using MTBE, stone recurrence rate was about 40% in solitary stones and about 70% in multiple stones over 5 years . Another challenge is to obtain the minimally invasive way of introducing the solvent into gallbladder. The last, but not least concern is safety because it is almost inevitable to have the proportion of solvent to be absorbed into duodenum or systemic circulation.
This study has several limitations. In the in vivo experiments using hamsters, although there was random assignment of each group, blind assessment of outcomes by investigators was not achieved. In addition, during experiments using hamsters, we could not compare the weights of gallstones before and after treatment because it was nearly impossible to measure the weights of gallstones before the treatment. Instead, in vivo gallstone dissolubility of each solvent was determined by comparing the weights of solvent-treated gallstones and control (DMSO)-treated gallstones.
In conclusion, MMP was found to have similar or higher dissolubility of gallstones and lesser toxicity than MTBE. Representatively, our in vitro experiments determined MMP to have 1.34 times (88.2% vs. 65.7%) higher 24-h dissolubility for cholesterol gallstones, and 1.75 times (50.7% vs. 29.0%) higher dissolubility for pigmented gallstones. Presently, the wide application of MTBE is limited by several toxicities, most of which originate from its higher evaporation rate due to a relatively lower boiling point. MMP wound be preferable to MTBE because of its lower evaporation rate and similar or higher dissolubility possibly by an additional chelating effect. If clinical trials support these conclusions, contact litholysis by MMP would not only replace conventional MTBE treatment considerably, but it will also be an attractive alternative to laparoscopic cholecystectomy in managing certain patients with gallstones.
Availability of data and materials
All data generated or analysed during this study are included in this published article and its additional files. For any additional information, please contact the corresponding author.
bcl-2-like protein 4
central nervous system
ethylenediamine tetraacetic acid
enzyme linked immunosorbent assay
human gallbladder epithelial cell
myeloid cell leukemia 1
methyl-tertiary butyl ether
nuclear magnetic resonance
proliferation cell nuclear antigen
tumor necrosis factor-α
Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver. 2012;6:172–87.
Little CJ, Dale AD, Whatley JA, Wickings JA. Methyl tert.-butyl ether: a new chromatographic eluent. J Chromatogr A. 1979;169:381–5.
Arco. Methyl tertiary butyl ether: acute toxicological studies; 1980.
Hellstern A, Leuschner U, Benjaminov A, Ackermann H, Heine T, Festi D, et al. Dissolution of gallbladder stones with methyl tert-butyl ether and stone recurrence: a European survey. Dig Dis Sci. 1998;43:911–20.
Allen MJ, Borody TJ, Bugliosi TF, May GR, LaRusso NF, Thistle JL. Cholelitholysis using methyl tertiary butyl ether. Gastroenterology. 1985;88:122–5.
Brandon JC, Teplick SK, Haskin PH, Sammon JK, Muhr WF, Hofmann AF, et al. Common bile duct calculi: updated experience with dissolution with methyl tertiary butyl ether. Radiology. 1988;166:665–7.
Di Padova C, Di Padova F, Montorsi W, Tritapepe R. Methyl tert-butyl ether fails to dissolve retained radiolucent common bile duct stones. Gastroenterology. 1986;91:1296–300.
Diaz D, Bories P, Ampelas M, Larrey D, Michel H. Methyl tert-butyl ether in the endoscopic treatment of common bile duct radiolucent stones in elderly patients with nasobiliary tube. Dig Dis Sci. 1992;37:97–100.
Foerster EC, Matek W, Domschke W. Endoscopic retrograde cannulation of the gallbladder: direct dissolution of gallstones. Gastrointest Endosc. 1990;36:444–50.
Kelly E, Williams JD, Organ CH. A history of the dissolution of retained choledocholithiasis. Am J Surg. 2000;180:86–98.
Neoptolemos JP, Hall C, O’Connor HJ, Murray WR, Carr-Locke DL. Methyl-tert-butyl-ether for treating bile duct stones: the British experience. Br J Surg. 1990;77:32–5.
Saraya A, Rai RR, Tandon RK. Experience with MTBE as a solvent for common bile duct stones in patients with T-tube in situ. J Gastroenterol Hepatol. 1990;5:130–4.
Van Sonnenberg E, Casola G, Zakko SF, Varney RR, Cox J, Wittich GR, et al. Gallbladder and bile duct stones: percutaneous therapy with primary MTBE dissolution and mechanical methods. Radiology. 1988;169:505–9.
Van Sonnenberg E, Hofmann AF, Neoptolemus J, Wittich GR, Princenthal RA, Willson SW. Gallstone dissolution with methyl-tert-butyl ether via percutaneous cholecystostomy: success and caveats. AJR Am J Roentgenol. 1986;146:865–7.
Pitt HA, McFadden DW, Gadacz TR. Agents for gallstone dissolution. Am J Surg. 1987;153:233–46.
Schoenfield LJ, Marks JW. Oral and contact dissolution of gallstones. Am J Surg. 1993;165:427–30.
Stein SE, Brown RL. Estimation of normal boiling points from group contributions. J Chem Inf Comput Sci. 1994;34:581–7.
Ji Y, Lin J, Peng X, Liu X, Li F, Zhang Y, et al. Behavioural responses of zebrafish larvae to acute ethosuximide exposure. Behav Pharmacol. 2017;28:428–40.
Yang X, Lin J, Peng X, Zhang Q, Zhang Y, Guo N, et al. Effects of picrotoxin on zebrafish larvae behaviors: a comparison study with PTZ. Epilepsy Behav. 2017;70:224–31.
Liang X, Souders CL 2nd, Zhang J, Martyniuk CJ. Tributyltin induces premature hatching and reduces locomotor activity in zebrafish (Danio rerio) embryos/larvae at environmentally relevant levels. Chemosphere. 2017;189:498–506.
Kammer B, Brink JA, Knoefel WT, Mueller PR, Prien EL, Ferrucci JT. Dissolution of calcified gallstones. Part II. Evaluation of edetic acid preparations for dissolution of residue after in vitro methyl tert-butyl ether treatment. Invest Radiol. 1994;29:454–8.
Kim IS, Myung SJ, Lee SS, Lee SK, Kim MH. Classification and nomenclature of gallstones revisited. Yonsei Med J. 2003;44:561–70.
Rege R, Ostrow J. Animal models of pigment and cholesterol gallstone disease. In: Muraca M, editor. Methods in biliary research. 1995. p. 203–43.
Leuschner U, Hellstern A, Schmidt K, Fischer H, Guldutuna S, Hubner K, et al. Gallstone dissolution with methyl tert-butyl ether in 120 patients—efficacy and safety. Dig Dis Sci. 1991;36:193–9.
Thistle JL, May GR, Bender CE, Williams HJ, LeRoy AJ, Nelson PE, et al. Dissolution of cholesterol gallbladder stones by methyl tert-butyl ether administered by percutaneous transhepatic catheter. N Engl J Med. 1989;320:633–9.
Ponchon T, Baroud J, Pujol B, Valette PJ, Perrot D. Renal failure during dissolution of gallstones by methyl-tert-butyl ether. Lancet. 1988;2:276–7.
Mehlman MA. Methyl-tertiary-butyl-ether (MTBE) misclassified. Am J Ind Med. 2001;39:505–8.
Bird MG, Burleigh-Flayer HD, Chun JS, Douglas JF, Kneiss JJ, Andrews LS. Oncogenicity studies of inhaled methyl tertiary-butyl ether (MTBE) in CD-1 mice and F-344 rats. J Appl Toxicol. 1997;17(Suppl 1):S45–55.
Mehlman MA. Dangerous and cancer-causing properties of products and chemicals in the oil-refining and petrochemical industry—Part XXII: health hazards from exposure to gasoline containing methyl tertiary butyl ether: study of New Jersey residents. Toxicol Ind Health. 1996;12:613–27.
Shaffer EA. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? Curr Gastroenterol Rep. 2005;7:132–40.
Tazuma S. Gallstone disease: epidemiology, pathogenesis, and classification of biliary stones (common bile duct and intrahepatic). Best Pract Res Clin Gastroenterol. 2006;20:1075–83.
Jaunoo SS, Mohandas S, Almond LM. Postcholecystectomy syndrome (PCS). Int J Surg. 2010;8:15–7.
Bernstein H, Bernstein C, Payne CM, Dvorak K. Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J Gastroenterol. 2009;15:3329–40.
Ge Z, Zhao C, Wang Y, Qian J. Cholecystectomy and the risk of esophageal and gastric cancer. Saudi Med J. 2012;33:1073–9.
Giovannucci E, Colditz GA, Stampfer MJ. A meta-analysis of cholecystectomy and risk of colorectal cancer. Gastroenterology. 1993;105:130–41.
Nogueira L, Freedman ND, Engels EA, Warren JL, Castro F, Koshiol J. Gallstones, cholecystectomy, and risk of digestive system cancers. Am J Epidemiol. 2014;179:731–9.
Reid FD, Mercer PM, Harrison M, Bates T. Cholecystectomy as a risk factor for colorectal cancer: a meta-analysis. Scand J Gastroenterol. 1996;31:160–9.
The authors thank Jennifer Lee for excellent technical assistance and Sang Jin Jeon for mouse husbandry.
This work was supported by the Clinical Research Institute Grant (5-2015-B0001-00175) CMCDJ-A-2011), Daejeon St. Mary’s Hospital, College of Medicine, the Catholic University of Korea. This research was financially supported by the KRICT (KK1703-G00) and National Research Council of Science and Technology (SKO1707C05).
Ethics approval and consent to participate
The study was approved by the Ethics Committee of Daejeon St. Mary’s hospital, the Catholic University of Korea (IRB code: DC09FZZZ0045). All animal studies were carried out in compliance with the guidelines of the Institute for Laboratory Animal Research in Korea. This animal study was approved by the Institutional Animal Care and Use Committee of the Clinical Research Institute at Daejeon St. Mary’s Hospital at the Catholic University of Korea (IRB No. CMCDJ-AP-2016-004).
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.